Full metadata record

DC FieldValueLanguage
dc.contributor.author최환근-
dc.contributor.authorJianming Zhang-
dc.contributor.authorEllen Weisberg-
dc.contributor.authorJames D. Griffin-
dc.contributor.author심태보-
dc.contributor.authorNathanael S. Gray-
dc.date.accessioned2015-12-03T00:50:39Z-
dc.date.available2015-12-03T00:50:39Z-
dc.date.issued201208-
dc.identifier.citationVOL 22, NO 16, 5297-5302-
dc.identifier.issn0960894X-
dc.identifier.other37842-
dc.identifier.urihttp://pubs.kist.re.kr/handle/201004/43078-
dc.description.abstractHG-7-85-01(22) and HG-7-86-01(26) are thiazolo[5,4-b]pyridine containing type II tyrosine kinase inhibitors with potent cellular activity against both wild-type and ‘gatekeeper’ mutant T315I- Bcr-Abl. Here we report on the ‘hybrid design’ concept and subsequent structure activity guided optimization efforts that resulted in the development of these inhibitors.-
dc.publisherBioorganic & medicinal chemistry letters-
dc.subjectT315I Bcr-Abl-
dc.subjectKinase inhibitor-
dc.subjectGatekeeper mutant-
dc.subjectType II inhibitor-
dc.subjectThiazolo[5,4-b]pyridine-
dc.titleDevelopment of ‘DFG-out’ inhibitors of gatekeeper mutant kinases-
dc.typeArticle-
Appears in Collections:
KIST Publication > Article
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE